PT  - JOURNAL ARTICLE
AU  - Munoz, Flor M.
AU  - Posavad, Christine M.
AU  - Richardson, Barbra A.
AU  - Badell, Martina L.
AU  - Bunge, Katherine
AU  - Mulligan, Mark J.
AU  - Parameswaran, Lalitha
AU  - Kelly, Clifton
AU  - Olsen-Chen, Courtney
AU  - Novak, Richard M.
AU  - Brady, Rebecca C.
AU  - Pasetti, Marcela
AU  - DeFranco, Emily
AU  - Gerber, Jeffrey S.
AU  - Shriver, Mallory
AU  - Suthar, Mehul S.
AU  - Moore, Kathryn
AU  - Coler, Rhea
AU  - Berube, Bryan
AU  - Kim, So Hee
AU  - Piper, Jeanna M.
AU  - Miller, Ashley
AU  - Cardemil, Cristina
AU  - Neuzil, Kathleen M.
AU  - Beigi, Richard
AU - DMID Study Group
TI  - COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004)
AID  - 10.1101/2022.06.13.22276354
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.13.22276354
4099  - http://medrxiv.org/content/early/2022/06/13/2022.06.13.22276354.short
4100  - http://medrxiv.org/content/early/2022/06/13/2022.06.13.22276354.full
AB  - Importance COVID-19 vaccination is recommended during pregnancy for the protection of the mother. Little is known about the immune response to booster vaccinations during pregnancy.Objective To measure immune responses to COVID-19 primary and booster mRNA vaccination during pregnancy and transplacental antibody transfer to the newborn.Design Prospective cohort study of pregnant participants enrolled from July 2021 to January 2022, with follow up through and up to 12 months after delivery.Setting Multicenter study conducted at 9 academic sites.Participants Pregnant participants who received COVID-19 vaccination during pregnancy and their newborns.Exposure(s) Primary or booster COVID-19 mRNA vaccination during pregnancy.Main Outcome(s) and Measure(s) SARS-CoV-2 binding and neutralizing antibody (nAb) titers after primary or booster COVID-19 mRNA vaccination during pregnancy and antibody transfer to the newborn. Immune responses were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination.Results In this interim analysis, 167 participants received a primary 2-dose series and 73 received a booster dose of mRNA vaccine during pregnancy. Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and cord blood compared to a primary 2-dose series (range 0.55 to 0.88 log10 higher, p<0.0001 for all comparisons). Although levels were significantly lower than to the prototypical D614G variant, nAb to Omicron were present at delivery in 9% (GMT ID50 12.7) of Pfizer and 22% (GMT ID50 14.7) of Moderna recipients, and in 73% (GMT ID50 60.2) of boosted participants (p<0.0001). Transplacental antibody transfer was efficient regardless of vaccination regimen (median transfer ratio range: 1.55-1.77 for binding IgG and 1.00-1.78 for nAb).Conclusions and Relevance COVID-19 mRNA vaccination during pregnancy elicited robust immune responses in mothers and efficient transplacental antibody transfer to the newborn. A booster dose during pregnancy significantly increased maternal and cord blood antibody levels, including against Omicron.Findings support continued use of COVID-19 vaccines during pregnancy, including booster doses.Trial Registration clinical trials.gov; Registration Number: NCT05031468; https://clinicaltrials.gov/ct2/show/NCT05031468Question What is the immune response after COVID-19 booster vaccination during pregnancy and how does receipt of a booster dose impact transplacental antibody transfer to the newborn?Findings Receipt of COVID-19 mRNA vaccines during pregnancy elicited robust binding and neutralizing antibody responses in the mother and in the newborn. Booster vaccination during pregnancy elicited significantly higher antibody levels in mothers at delivery and cord blood than 2-dose vaccination, including against the Omicron BA.1 variant.Meaning COVID-19 vaccines, especially booster doses, should continue to be strongly recommended during pregnancy.Competing Interest StatementF.M.M. is an investigator of pediatric studies of COVID-19 vaccines for Pfizer and for a pediatric remdesivir study conducted by Gilead Sciences Inc F.M.M. serves as investigator on projects supported by an NIH contract for a Vaccine Treatment and Evaluation Unit (VTEU) F.M.M. serves as member of the Data Safety monitoring Board (DSMB) for clinical trials conducted by Pfizer Moderna Meissa Vaccines Virometix and the NIH F.M.M. is a member of the American Academy of Pediatrics Committee of Infectious Diseases (COID) and the Immunization Expert Group of the American College of Obstetrics and Gynecology (ACOG) and Co-Chair of the COVAX Maternal Immunization Working Group. K.M.N. is a member of the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization. K.M.N. serves as co-investigator on an NIH contract for a Vaccine Treatment and Evaluation Unit (VTEU). K.M.N. serves as Co-chair of the NIH COVID Prevention Network (CoVPN) and served as an investigator for Phase I/II Pfizer COVID-19 vaccine grant with a grant to the institution but no salary support. K.M.N. receives grants from Pfizer to conduct clinical trials of COVID vaccines through the Center for Vaccine Development and Global Health at University of Maryland in Baltimore. She receives grants from NIH to participate in overall organization of COVID-19 vaccine trials and for participation in vaccine trials. M.J.M. conducts laboratory research and clinical trials with contract funding for vaccines or MABs vs SARS-CoV-2 with Lilly and Pfizer and Sanofi and receives personal fees for Scientific Advisory Board service from Merck Meissa Vaccines Inc. and Pfizer. M.S.S. served as an advisor for Moderna (ended December 2021) and is currently serving as an advisor for Ocugen Inc. B.A.R. currently holds a position on a DSMB for clinical trials at Gilead Sciences Inc. R.C.B. at Cincinnati Childrens Hospital receives research grant support for clinical trials from PATH and Astra Zeneca and Pfizer on which she serves as co-investigator. B.B. owns shares in HDT Bio Corp. J.S.G. receives research funds from NIH for Moderna KidCOVE study. R.M.N. is a paid advisor to Gilead and an investigator on NIH-funded trials of Moderna and Pfizer and Janssen vaccines. J.R.K. is a medical speaker for Abbott Nutrition with the UIC team. A.R.F. holds research grants from Pfizer and Janssen and Merck and Cyanvac and Biofire Diagnostics and serves on the DSMB for Novavax. N.R. receives funds to conduct industry trials from Pfizer and Merck and Sanofi-Pasteur and serves as a safety consultant for EMMES and ICON. R.W.F. Jr. has received funds to conduct industry trials from Pfizer and Moderna and Astra Zeneca and serves on advisory boards for Merck and Sanofi-Pasteur and Johnson and Johnson and Seqirus and serves on an ICON-sponsored DSMB for a C difficile study.Funding StatementSupported by the Infectious Diseases Clinical Research Consortium (IDCRC) through the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), under award numbers UM1AI148684, UM1AI148575, UM1AI148372, UM1AI148452, UM1AI148576, UM1AI148574, UM1AI148450, UM1AI148685, UM1AI148689, and UM1AI148373. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval of this protocol was received on May 28, 2021 by Vanderbilt University Medicine Center IRB, a single IRB as part of an NIH-funded consortium, IDCRC. Written informed consent was obtained from each participant.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected for the study will be made available to others as a de-identified patient data set after finalization of clinical study report at the discretion of the IDCRC. Analyses of data, including data from staged analyses, will be available for presentation at scientific meetings and publication to inform the scientific community. If preliminary analyses are considered of public health importance or relevant to inform research, development, and implementation of SARS-CoV-2 vaccine in pregnancy, results may be shared with public health officials and partners to inform the global scientific community. The study will be conducted in accordance with the NIH Public Access Policy publication and data sharing policies and regulations. To request study data once complete, contact Flor M. Munoz, florm{at}bcm.eduACOGAmerican College of Obstetricians and GynecologistsBAU/mLBinding Antibody UnitsCoVPNCOVID Prevention NetworkDMIDDivision of Microbiology and Infectious DiseasesDSMBData Safety monitoring BoardFRNTFocus reduction neutralization titerGMTGeometric mean titerIDCRCInfectious Diseases Clinical Research ConsortiumIgGImmunoglobulin GIQRsInterquartile rangesMSDMeso Scale DiscoverynAbNeutralizing antibodiesNIHNational Institutes of HealthRBDReceptor binding domainSpikeFull-length spikeU.S.United StatesVTEUVaccine Treatment and Evaluation UnitWHOWorld Health Organization